In PAAD, a complex multistep disease driven by mutations in KRAS, TP53, CDKN2A, and SMAD4, METTL16 is consistently downregulated across tissues and cell lines harboring these driver mutations. The gene discussed is METTL16; the disease is pancreatic adenocarcinoma.